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1. INTRODUCTION AND HISTORICAL PERSPECTIVE 
 
Germ cell testicular cancer (TC) is a relatively uncommon disease, accounting for 
approximately 2% of all incident cancer cases in Norway in 2006.1  However, it is an 
important disease as it represents a highly curable cancer, and primarily affects young men 




Figure 1. Age-specific incidence rates of TC 2000-2004. The Norwegian Cancer Registry 2004. 
 
 
The prognosis of metastatic TC was poor less than half a century ago. Based on the 
understanding of the pattern of lymphatic spread, retroperitoneal lymph node dissection 
(RPLND) was developed as a treatment option for patients with limited retroperitoneal 
disease. This technique yielded 5-year survival rates for selected patients at 46% already in 
the 1950s.2 The original surgical technique involved bilateral, non-nerve sparing operations 
with considerable morbidity, mainly retrograde ejaculation. In the early 1980s, modified 
unilateral and nerve sparing techniques were introduced, aiming at reducing the side-effects.3 
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Today, the RPLND procedure is primarily used as treatment post chemotherapy for non-
seminoma patients with initial retroperitoneal disease.4 Additionally, it is a diagnostic 
procedure for clinical stage I non-seminoma patients internationally.5  
 
Radiotherapy (RT) is a treatment modality which evolved during the 20th century. 
Traditionally, patients with localized disease or retroperitoneal lymph node metastases were 
treated with high-voltage RT since the 1950/60s.6,7 This treatment yielded excellent long-term 
results for pure seminoma patients, while those with lymphatic spread from non-seminoma 
had a worse prognosis.7 Irradiation is today a treatment option primarily for seminoma 
patients with localized disease or small retroperitoneal metastases.4,5   
 
A broad spectrum of chemotherapy agents was tested in disseminated germ cell TC during the 
1960s and 1970s. Vinblastine and bleomycin were reported to have significant antitumor 
activity, and the combination of these two led to an overall response rate at 75% including 
complete remission in 32% of the patients, some of which were durable responses.8 A major 
advance was the discovery of cis-diammine-dichloroplatinum (cisplatin) activity in germ cell 
TC.9 In the first study combining cisplatin, vinblastine and bleomycin (CVB) in patients with 
metastatic TC, 74% achieved a complete remission,10 and the 5-year survival was 64%.11 
Proving that patients with metastatic cancer could be cured with chemotherapy, the study by 
Einhorn et al10 is still a landmark study in modern oncology. 
 
Today, germ cell TC is a highly curable disease (Figure 2). Since most TC patients are 
relatively young at diagnosis, they can expect to live for another 30-50 years after being 
successfully treated for TC. The growing number of testicular cancer survivors (TCS) 
combined with their long life expectancy has lead to an increased attention towards treatment- 
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related long-term morbidity. Already in early 1980, Raynaud’s phenomenon was described as 
a common toxicity after combination chemotherapy for TC.12 Several studies published 
around 1990 further indentified ototoxicity, decreased renal function, peripheral neuropathy, 
sexual dysfunction, hypertension, obesity and hypercholesterolemia as possible late effects 
after cisplatin-based chemotherapy.13-18 However, most of these studies included small patient 
series and many of them included only chemotherapy-treated patients.  
 
The need for more knowledge regarding long-term treatment-related toxicity stimulated the 
initiation of a large, national, unselected follow-up survey which focused on several aspects 
of somatic and psychosocial health in long-term TCS. This survey was conducted as a 
Norwegian Urological Study Group (NUCG) study and involved all five regional university 
clinics in Norway. This thesis is based on the results of the cardiovascular and pulmonary 




Worldwide, the incidence of TC is highest in Northern Europe and North America, while Asia 
and Africa have the lowest incidence rates.19 Norway has one of the highest incidence rates of 
germ cell TC in the world.20 In total, 255 men were diagnosed with TC in Norway in 2006, 
corresponding to an age-adjusted incidence rate at 10.4 per 100 000.1 Although TC is a 
relatively rare disease compared with other malignancies, TC is the most common 
malignancy among 15-44 year old males.1 Only 15% of Norwegian men diagnosed with TC 
in 2006 were older than 50 years. The incidence rates are increasing in most European 
countries, including Norway (Figure 3), while mortality rates are declining.20  
 
 
Figure 3. Age-adjusted incidence rates of TC 1953-2004. Norwegian Cancer Registry 2004.  
 
The overall 5-year cancer specific survival in Norway is currently 96%, while approximately 
80% of patients with advanced disease are cured.1 This cure rate is the highest of any solid 
tumor and is the result of the chemotherapeutic agent cisplatin,10,21 better diagnostic tools and 
a multimodal treatment strategy where surgery and either chemotherapy or RT are combined.4  
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The combination of increasing incidence and high TC cure rates has lead to an increasing 
number of TCS. In 2006 there were 5253 Norwegian males alive with a prior TC diagnosis, 
representing a 56% increased prevalence during a 10-year period.1 This constitutes 3% of all 
Norwegian individuals with a previous cancer diagnosis. On the other hand, TC deaths 
accounted for only 0.1% of all cancer deaths in Norway in 2004. Although there are 
indications for higher mortality rates among long-term TCS,22,23 these cancer survivors have a 
life expectancy which is almost comparable to healthy age-matched men.  
 
2.2 Risk factors for testicular cancer  
The increasing incidence rate of TC during the last 50 years may be related to an increased 
exposure to different environmental carcinogens. However, the etiology of TC is not well 
understood.24 Since TC primarily occurs in early adult life, it is likely that the carcinogenetic 
process is initiated already in utero or in early childhood. The increasing incidence rate 
follows a birth cohort pattern, indicating that the lifetime risk of having TC is highly 
dependent on year of birth.20,25,26 The birth cohort effect implies that the risk factors for TC 
exert their effect in utero or early in life. 
 
Family studies have demonstrated that TC may have an inherited susceptibility, with a 3-10 
fold increased risk of having TC for first degree family members of TC patients.27,28  Familial 
risks may be due to shared genes and/or shared childhood environment. Immigrant studies 
have shown that the TC risk among first-generation immigrants reflected the risk in the 
country of origin, while second-generation immigrants had a risk similar to that of natives in 
the country of immigration.29,30 These studies have indicated that environmental influence 
early in life contributes to the TC risk.  
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It is well established that cryptorchidism (undescendend testes) is associated with an 
increased risk of TC, with an odds ratio (OR) at 4.8 in a large meta-analysis.28 Subfertility and 
genital malformations are also associated with increased risks of developing TC.24,28,31 It is, 
however, unclear whether cryptorchidism, subfertility and genital malformations are risk 
factors for TC. These conditions may instead possibly share common etiological factors with 
TC, in what is called the testicular dysgenesis syndrome (TDS).32 It has been hypothesized 
that the testicular dysgenesis origins in utero, and that TDS is initiated by environmental 
factors such as hormone-disrupting compounds acting on both the mother and the fetus.32,33 
The precursor of invasive TC, carcinoma in situ, has features of transformed gonocytes and is 
also probably a part of the TDS.33  
 
2.3 Histopathology and tumor markers  
About 95% of all malignant tumors in the testicles originate from the primordial germ cells, 
the cells predestined to become spermatozoa. Lymphomas, sarcomas and other malignant 
tumors constitute the remaining 5%.34 Germ cell testicular tumors are broadly divided into 
two groups, seminomas and non-seminomas, comprising about 50% of cases each. According 
to the World Health Organization (WHO) classification, the non-seminomas consist of one or 
several histological elements (embryonal carcinoma, yolk sac tumor, choriocarcinoma, and 
teratoma), while seminomas only consist of seminoma elements.35  
 
Non-seminomas arise in the late teens/early adult life and are highly aggressive tumors, with 
approximately 50% of patients displaying metastatic disease at the time of diagnosis. 
Seminomas are less aggressive tumors and generally affect men in their third to fourth decade 
of life; sometimes, however, older men are affected. Germ cell tumors may also arise outside 
of the testicles (extragonadal germ cell tumors), mainly in the mediastinum or 
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retroperitoneum. These tumors have a less favorable prognosis, require specialized treatment 
and are not further described in this thesis. 
 
Human chorionic gonadotropin (HCG) is produced by syncytiotrophoblastic components 
(choriocarcinoma), while α-fetoprotein (AFP) is a glycoprotein produced by embryonal 
carcinoma elements of germ cell cancers. These tumor markers are essential in the diagnosis, 
prognosis and treatment of patients with germ-cell TC, and should be determined both before 
and after orchiectomy, and during and after further treatment. Tumor marker decline less than 
the half-life during chemotherapy may indicate treatment resistance, and warrants treatment 
intensification or second line chemotherapy.  
 
Serum HCG and/or AFP is elevated in 85% of patients with disseminated non-seminoma TC, 
while around 10% of seminoma patients have elevated HCG.34 The degree of tumor marker 
elevation is a prognostic factor together with the number and site of visceral metastases.21  
 
2.4 Treatment principles 1980-1994 
Treatment of Norwegian TC patients during the last decades have been according to the 
Swenoteca collaboration36-38 or EORTC and MRC protocols.39-44 All patients were initially 
orchiectomized. After histological verification of the germ cell TC diagnosis, all patients 
underwent X-ray or computed tomography (CT) of thorax and CT of abdomen and pelvis. If 
necessary, supplemental imaging was performed. Clinical staging was performed according to 





Table 1. The Royal Marsden Staging System.45  
Stage     Description  






No radiological evidence of metastases, but positive markers after orchiectomy 
(IMk) or involvement of retroperitoneal lymph nodes (II). 
Maximum diameter of metastases < 2 cm 
Maximum diameter of metastases 2-5 cm 
Maximum diameter of metastases >5 cm 
III  Involvement of supradiaphragmatic lymph nodes. 
A, B and C as for stage II. 
IV  Hematological metastases. Involvement of lungs, liver, skeleton and/or brain. 
 
 
2.4.1 Seminomas  
Within this period, most patients with early stages (≤ IIA) of seminoma were treated with 
infra-diaphragmatic RT. The dog-leg technique involving radiation to the para-aortic and 
ipsilateral iliac nodes was generally used (Figure 4), but some patients received radiation to 
the para-aortic area only, as this technique was introduced at one institution in 1989.43 A very 
small number of patients received additional mediastinal irradiation (stage II and III) as this 
treatment option was abandoned as late as the early 1980s.13 From early 1980s to mid 1990s 
the standard RT dose was gradually reduced from 36-40 Gy to 25.2-30 Gy. The majority of 
patients with more advanced disease (≥ IIB) received cisplatin-based chemotherapy followed 
in some cases by retroperitoneal surgery or radiation.  
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Figure 4. Dog-leg radiotherapy field.      Figure 5. An example of left modified retro-             




Patients with early stages (≤ IIA) of non-seminomas were until late 1980s routinely treated 
with primary RPLND (Figure 5), followed by cisplatin-based chemotherapy if metastases was 
detected. Later, the diagnostic RPLND was replaced by surveillance or adjuvant 
chemotherapy for clinical stage I patients, dependent on risk-factor assessments.38 Patients 
with stages ≥ II received 3-4 courses of cisplatin-based combination chemotherapy37,42 
followed by RPLND and further chemotherapy was administered in case of malignant cells in 
the biopsy specimen. Residual tumors in the lungs and other organs after chemotherapy 
treatment were resected whenever possible. 
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2.4.3 Chemotherapy regimens and the most frequently used agents 
Table 2. Chemotherapy regimens. 








30 mg in total 
 
iv infusion day 1-5 each cycle 
iv bolus day 1 and 2 each cycle 






  20 mg/m2 
100 mg/m2 
  30 mg in total  
 
iv infusion day 1-5 each cycle 
iv infusion day 1-5 each cycle 
iv bolus day 1, 5 and 15 each cycle 
 
All patients participating in this follow-up study were treated after the introduction of 
cisplatin in late 1970s.10 The majority of chemotherapy-treated patients received cisplatin in 
combination with bleomycin and either vinblastine (CVB) or etoposide (BEP, Table 2). The 
original CVB regimen included maintenance therapy with vinblastine. The maintenance 
treatment was omitted in 1981 due to the lack of effect.48 After 1987, vinblastine was replaced 
by etoposide due to improved survival for those with advanced disease and less toxic 
effects.47 Standard treatment for the patients included in the present survey consisted of three 
to four cycles of CVB or BEP given at three-week intervals. Some patients received high-
dose cisplatin regimens as primary treatment,37,49 and/or more than four cycles44 of cisplatin-
based chemotherapy due to poor prognosis, inadequate response, progressive disease or 
relapse. Also, some patients received other cisplatin-based combinations or carboplatin 
instead of cisplatin41,42 due to inclusion in research protocols.  
 
Cisplatin is a platinum compound which forms cross-links with DNA19 and ultimately induces 
apoptosis. This chemotherapy agent is excreted renally, but the secretion is often incomplete 
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and cisplatin has been detected in plasma up to 20 years after administration of cisplatin-
based chemotherapy.50 The major dose-limiting toxicity of cisplatin is renal, which in some 
cases are manifested as acute interstitial nephritis. High fluid intake and forced diuresis during 
treatment is a routine prophylactic measure which reduces the incidence of renal toxicity. 
Other acute side-effects include severe nausea and vomiting, ototoxicity, Raynaud’s 
phenomenon and neurotoxicity. 
 
Bleomycin is an antibiotic agent which exerts its antitumor effect by induction of free 
radicals,19 ultimately leading to tumor cell death. This drug is eliminated renally. Bleomycin 
can be deactivated by bleomycin hydrolase, an enzyme which is found in normal and 
malignant cells. Due to the lack of this enzyme in the skin and lungs, bleomycin toxicity 
occurs primarily in these organs.51 The most serious side-effect is pneumonitis, which 
occasionally progresses to pulmonary fibrosis during or shortly after treatment. 
 
Vinblastine is a vinca alkaloid which mainly interacts with tubulin and disturbs the 
microtubule function, leading to metaphase arrest.19 It is metabolized and excreted primarily 
by the hepatobiliary system. Neutropenia is the major dose-limiting toxicity. Neurotoxicity is 
also a common side-effect, including peripheral polyneuropathy.47  
 
Etoposide is an epipodophyllotoxin with topoisomerase as its target of action.19 This drug is 
primarily excreted renally. Myelosuppression is the major dose-limiting toxicity. 
 
2.5 Cardiovascular risk factors and the metabolic syndrome 
Atherosclerotic cardiovascular disease (CVD) results in high mortality rates and is considered 
a major health problem. Although CVD mortality rates are declining in Western Europe,52 
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CVD is the leading cause of death in Norway, accounting for 35% of all deaths in 2006.53  
CVD comprises a group of chronic diseases including coronary heart disease (CHD), stroke 
and peripheral arterial disease. These conditions cause serious disabilities for a large number 
of individuals, and the medical treatment involves considerable expenses for the society.  
 
Non-modifiable atherosclerotic cardiovascular (CV) risk factors include age, sex and a family 
history of CVD.54-56 In particular, CHD tends to cluster in families, and a positive family 
history of premature CHD is an independent risk factor.55 At any given age, men are at a 
greater risk for CV mortality than women.56 The sex difference is partially explained by a 
higher prevalence of modifiable CV risk factors in men.57 The most important modifiable 
atherosclerotic CV risk factors include hypertension, obesity, an unfavorable lipid profile, 
diabetes, smoking, an unhealthy diet and lack of physical activity.58-60 Identification of 
individuals with any or several of these risk factors is important in order to initiate lifestyle 
interventions and, if necessary, primary prophylaxis to prevent the development of CVD.   
 
The metabolic syndrome is a constellation of metabolic abnormalities which was first 
characterized by Reaven as “syndrome X” in 1988.61 Later, WHO,62 National Cholesterol 
Education Program (NCEP) expert panel63 and the International Diabetes Federation64 have 
published definitions of the metabolic syndrome. These definitions differ in several aspects as 
outlined in Table 3. The most widely accepted metabolic risk factors included in the 
metabolic syndrome are dyslipidemia, hypertension, abdominal obesity and insulin resistance. 
The metabolic syndrome is important due to its association with diabetes, CV morbidity, CV 
mortality and overall mortality.65-69 Thus, this syndrome is important in identifying 
individuals at an increased CVD risk. 
Table 3. Definitions of the metabolic syndrome.  
 
WHO definition62 NCEP definition63 IDF definition64 
1. Diabetes, impaired glucose tolerance or insulin 
resistance 
At least three of the following: 1. Central obesity, waist girth ≥ 94 cm for men,    
≥ 80 cm for women (Europe) 
2. Plus two or more of the following components:
   A. High blood pressure ≥ 160/90 mmHg 
A. Blood pressure ≥ 130/85 mmHg or med 
B. Serum HDL-C < 1.0 mmol/l in men,      
2. Plus two or more of the following components:    
A. Blood pressure ≥ 130/85 mmHg or med      
B. Serum TG ≥1.7 mmol/l and/or serum HDL-
C < 0.9 mmol/l in men, 1.0 mmol/l in women 
< 1.3 mmol/l in women  
C. Serum TG ≥1.7 mmol/l 
B. Serum HDL-C < 1.0 mmol/l in men, 
< 1.3 mmol/l in women 
C. Central obesity (males: waist-to-hip ratio    
>0.90, females >0.85) and/or BMI ≥ 30 kg/m2 
D. Microalbuminuria 
D. Waist girth: > 102 cm in men, > 88 cm 
in women  
E. Fasting blood glucose ≥ 5.6 mmol/l 
C. Serum TG ≥ 1.7 mmol/l and /or specific 
treatment of lipid abnormalities  
D. Fasting blood glucose ≥ 5.6 mmol/l 
  (includes diabetes)* (includes diabetes) 
Abbreviations: WHO, World Health Organization; NCEP, National Cholesterol Education Program; IDF, International Diabetes Federation; TG, 
triglycerides; med, medication; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index. 




It has been debated whether the metabolic syndrome is merely a clustering of unrelated risk 
factors, or a constellation of risk factors linked through a common underlying mechanism.65  
Criticism has been raised against the term “metabolic syndrome”, as the risk associated with 
the syndrome is not greater than the sum of its parts.71 It is, however, beyond the scope of this 
thesis to further discuss possible limitations regarding the metabolic syndrome.  
 
2.6 Treatment-related long-term toxicity in testicular cancer survivors 
2.6.1 General aspects 
During the early 1980s, the overall 5-year germ cell TC survival was rising to rates >90%.1 
As overall survival today has surpassed 95%, clinical studies increasingly focus long-term 
toxicity in TCS. The research of late effects from germ cell TC treatment is in general 
retrospective, and has identified toxicities related to obsolete treatment strategies such as the 
identification of increased risk for cardiac disease after mediastinal irradiation in seminoma 
patients.6,72,73 However, cisplatin-based chemotherapy is still a cornerstone in the treatment of 
disseminated TC. Except for etoposide substituting vinblastine in 1987,47 the first line 
chemotherapy schedule have been basically unchanged since the introduction of cisplatin-
based chemotherapy in 1977.10 
 
The acute renal toxicity observed during cisplatin-based chemotherapy may in up to 30% of 
the patients result in persisting subclinical impaired renal function,74 primarily after high 
cumulative cisplatin doses or when chemotherapy and irradiation is combined.74,75 Persisting 
hypomagnesemia is a frequent finding after cisplatin-based chemotherapy,76 and is probably 
the result of tubular dysfunction. Raynaud’s phenomenon, characterized by transient 
vasoconstriction of digital arteries, is a common acute side-effect related to chemotherapy and 
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persists in 30-40% of the patients.16,76,77 Chemotherapy-induced endothelial damage is a 
possible mechanism responsible for the development of Raynaud’s phenomenon.  
 
Other long-term somatic adverse effects after multimodality TC treatment include ototoxicity, 
peripheral neuropathy, infertility, Leydig cell impairment and an increased risk of secondary 
cancers.15,76,78-82 Most of these side-effects are related to cisplatin-based chemotherapy. The 
increased risk for secondary cancer is also attributable to infradiaphragmatic irradiation, either 
alone or in combination with chemotherapy.80-82 
 
2.6.2 Cardiovascular risk factors and morbidity 
During the second half of the 1980s there were case reports describing acute CVD during or 
shortly after cisplatin-based combination chemotherapy.83,84 Several later papers have focused 
on CV risk factors and CVD as possible late effects following chemotherapy for TC.14-
16,18,76,77,85,86 These studies have identified hypertension, obesity, and hypercholesterolemia as 
possible late side-effects due to chemotherapy. They reported rates of cardiac events between 
1% and 6% several years after treatment.  
 
The study by Meinardi et al86 was the first to make comparisons of cardiac event rates with 
the normal population, and found an observed/expected ratio for cardiac disease at 7.1 (95% 
CI 1.9-18.3), accompanied by an unfavorable CV risk profile. This study was published in 
2000, while our follow-up survey was being conducted. All these prior reports had, however, 
limited power due to small patient series (<100 patients included), inclusion of chemotherapy 
treated patients only, and generally the lack of control groups.  
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In 2003 the first large report describing CVD in a large cohort of TCS (n=992) was published 
by Huddart et al.87 They found a more than 2-fold increased risk for CVD after chemotherapy 
alone, irradiation alone or both modalities combined in comparison to surveillance cases, with 
a median follow-up of 10.2 years. The authors did not observe any differences between the 
treatment groups with regard to blood pressure, BMI and cholesterol levels, but their data 
were not age adjusted.  
 
Another large study published by Zagars et al in 2004 described cardiac mortality in 453 men 
previously treated with RT for stage I/ II seminoma with a median follow-up of 13.3 years.6 
The majority of patients had been treated with infradiaphragmatic irradiation only, while 71 
(16%) had received additional prophylactic mediastinal irradiation (PMI). The authors 
observed a significantly elevated cardiac mortality risk among patients receiving PMI with a 
standardized mortality rate (SMR) at 2.04, with the highest risk for those followed beyond 15 
years. The Zagars study also noted excess cardiac deaths among those not receiving PMI, but 
only in those with ≥ 15 years of follow-up (SMR 1.80). The study described only cardiac 
mortality, and did not report the prevalence of cardiovascular risk factors.  
 
The first study describing the prevalence of metabolic syndrome in TCS was presented in 
2005.88 In this Dutch study, Nuver et al reported a higher prevalence of metabolic syndrome 
in both cisplatin-treated (26%) and surveillance patients (36%) compared with healthy 
controls (9%). Surprisingly, they found the highest prevalence in stage I patients, although not 
significantly different from cisplatin-treated patients (p=.23). Thus, based on previously 
published studies, several questions regarding the development of CV risk factors in long-
term TCS remained unanswered. 
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2.6.3 Pulmonary toxicity  
Pulmonary toxicity was early identified as the major dose-limiting side-effect of bleomycin 
treatment.89,90 Bleomycin may cause pneumonitis, occasionally progressing to pulmonary 
fibrosis during or shortly after treatment.51,77,91,92  Patients with bleomycin pulmonary toxicity 
(BPT) present with non-productive cough, exertional dyspnoea and sometimes fever, and the 
radiological findings are bilateral infiltrates.51,93 As there are no agreed criteria to define BPT, 
the prevalence of patients with non-fatal BPT varies in different studies. Fatal BPT has been 
reported to occur in 1-3% of patients treated with bleomycin.92,94  
 
It is essential to detect pulmonary toxicity prior to the onset of severe pulmonary symptoms 
during or after TC treatment. Pulmonary function assessments seem to be the most proper 
tool.51 A decrease in the lung transfer capacity for carbon monoxide (TLCO) measured during 
or shortly after chemotherapy treatment has been indicative of subclinical BPT in several 
studies,90,91,95-97 but these reductions in TLCO were generally normalized years after 
treatment. Spirometry assessments have also been performed during and after chemotherapy 
treatment to identify subclinical pulmonary disease. A decreased vital capacity (VC) and/or 
functional vital capacity (FVC) was observed during chemotherapy in the majority of 
previous studies. However, all were normalized at follow-up.90,93,96,97 In two small clinical 
studies, spirometry changes during or after treatment were not observed.95,98  
 
The majority of previously published studies on pulmonary function in TC patients have 1) 
focused on treatment with bleomycin, 2) included small numbers of individuals and/or 3) had 
a limited follow-up period. With the exception of BPT, no conclusions regarding long-term 
effects of TC treatment on the pulmonary function in an unselected TCS population can be 
drawn from these previous publications. 
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3. AIMS OF THE THESIS 
 
Based on the existing knowledge as described in chapter 2, the purpose of this thesis is to 
examine any associations between TC treatment and CV risk factors, the metabolic syndrome 
and pulmonary function in a large, unselected national cohort of long-term TCS. More 
specifically, the aims are to address the following questions: 
 
1. Are there any associations between blood pressure, BMI, hypertension and obesity and the 
different treatment modalities (surgery, RT and chemotherapy)? (Paper I) 
2. Do TCS differ from controls representing the general population with respect to any of 
these CV risk factors? (Paper I) 
3. Does the prevalence of the metabolic syndrome by using a modified NCEP definition 
differ according to previously administered treatment? (Paper II) 
4. Do TCS differ from controls with respect to the metabolic syndrome? (Paper II) 
5. Are there any associations between pulmonary function assessed by spirometry and a 
questionnaire and the different treatment modalities (surgery, RT and chemotherapy)? 
(Paper III) 
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4. SUBJECTS AND METHODS 
4.1 Testicular cancer survivors survey 
4.1.1 Study population 
During the period 1998 to 2002, the five academic oncology departments in Norway 
conducted a follow-up survey focusing on several aspects of somatic and psychosocial health 
in long-term TCS. All Norwegian survivors of unilateral germ cell TC who had been treated 
in the period 1980 to 1994 and aged between 18 and 75 years were identified through the 
Cancer registry of Norway and the five regional university hospitals. They were invited to 
participate in this cross-sectional national multicenter survey (Appendix I), which consisted of 
a comprehensive mailed 219-item questionnaire and an outpatient visit including laboratory 
tests, clinical examination, audiometry, spirometry at three of the centers and an optional 
semen analysis. Patients with extragonadal germ cell tumors, bilateral orchiectomy for any 
reason, secondary malignancy except skin cancer, or mental retardation were excluded. The 
study was approved by the Committee for Medical Research Ethics, Region South. 
 
In total 1814 patients met the eligibility criteria and were invited to participate in the study. 
Overall 1463 (81%) signed the informed consent form and participated in the study by either 
completing the questionnaire (n=1438) and /or participating in the clinical examination 
including laboratory tests (n=1289). There were overall 351 non-responders (Figure 6). Data 
on responders vs. non-responders are presented in Table 4. Additionally, one patient has later 
withdrawn from the database after paper II was prepared.  
 
All patients with clinical examination data (n=1289) formed the study population in paper I 
(Figure 6). In paper II, we used data from the clinical examination, laboratory tests and the  
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1814 testicular cancer survivors were invited 
Overall 1463 (81 %) responders: 
• 1264 (70 %) both questionnaire 
      and clinical examination 
• 25 clinical examination only  
• 174 questionnaire only 
1049 survivors with spirometry data 
included in Paper III 
1289 (71%) with data from the clinical 
examination included in Paper I  
129 patients aged 
above 60 years were 
excluded 
Spirometries were 
performed at three of the 
participating centers 
Figure 6. Study populations. 
Overall 351 (19 %) non-responders: 
• 340 did not respond to invitation 
• Ten were untraceable 
• One had died 
1264 with data from both the clinical 
examination and questionnaire were 
eligible for participating in Paper II 
1135 survivors aged ≤ 60 years were 
included in Paper II 
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Age at diagnosis, years  















Royal Marsden stage, n (%)  
   Stage I 
   Stage IM/II 
   Stage III 
   Stage IV  
 
  1022 (70) 
    295 (20) 
      32   (2)  
    114   (8)  
 
   238 (68) 
     75 (21) 
       8   (2) 
     30   (9) 
 
0.90 




   728 (50) 
   735 (50) 
 
   180 (51) 
   171 (49) 
 
0.61 
Treatment group, n (%) 
Surgery  
Radiotherapy  
Chemotherapy cis ≤ 850  
Chemotherapy cis > 850  
 
   275 (19) 
   624 (43) 
   453 (31) 
   111   (8) 
 
     77 (22) 
   142 (41) 
   114 (32) 





questionnaire. Since the metabolic syndrome is highly prevalent among the elderly,99 129 men 
aged above 60 years were excluded from the 1264 study patients with both questionnaire and 
clinical examination data, leaving 1135 TCS in the study population. Only three of the five 
participating hospitals (the Norwegian Radium Hospital [NRH, n=711], Haukeland 
University Hospital [Haukeland, n=232] and the University Hospital of North Norway [UNN, 
n= 106]) investigated the participants with spirometries as part of their outpatient visit. These 
1049 TCS formed the study population in paper III.  
 
Data regarding histology, initial staging and treatment as well as blood pressure, weight and 
height at the time of diagnosis were obtained from medical records. The cumulative cisplatin 
doses, not the number of courses or doses for other agents, were initially reported (paper I). 
During 2006, it was possible to retrieve complete details regarding regimes, doses and relapse 
treatment from the hospital records for all chemotherapy treated patients (paper II and III). 
 26
4.1.2 Treatment groups 
Principles for treatment of TC in Norway in the period 1980 to 1994 are described in chapter 
2. To evaluate the impact of specific treatment on the different outcome variables, the TCS 
were categorized into treatment groups according to initial and eventual relapse treatment:  
(1) Surgery only, including orchiectomy and possibly RPLND;  
(2) Radiotherapy (RT) only; 
(3) Chemotherapy with a cumulative dose of cisplatin≤850 mg (cis≤850);  
(4) Chemotherapy with a cumulative dose of cisplatin>850 mg (cis>850).  
This categorization was applied in paper I and II. In paper III, we additionally allocated 
chemotherapy treated patients (any dose) who underwent pulmonary surgery, into a separate 
group (cis/pulmsurg) as it is well known that thoracic surgery may influence the pulmonary 
function.100 
 
The cut-off point for the two chemotherapy groups was set at 850 mg cisplatin to roughly 
differentiate between 1) patients who received standard four courses or less and 2) those who 
received more than four courses or “higher dose” chemotherapy regimens due to a poor 
prognosis, inadequate response, progression or relapse. The cut-off at 850 mg was chosen to 
include men treated with maximum four cycles in the lower dose group, including those with 
a body surface area of 2.1 m2, which is rather common in Norway. Doses higher than 
corresponding to 2.1m2 (840 mg) are seldom prescribed. This cut-off also allocates those who 
were treated with “high-dose” cisplatin-based chemotherapy (BEP40 and BEP60) into the 




Clinical examination, laboratory tests and spirometries 
Resting blood pressure was measured manually or with an automatic device. Weight was 
measured with the individual in light clothing and without shoes. BMI was calculated as 
weight in kilograms divided by the square of height in meters (kg/m2). Blood samples were 
drawn non-fasting by venipuncture at each hospital laboratory primarily between 0800 and 
1200 hours. In this thesis, levels of serum cholesterol, serum magnesium (Mg) and serum 
testosterone have been reported. Serum total cholesterol was measured enzymatically, and 
serum Mg was measured by a colorimetric endpoint method. Levels of serum total 
testosterone were determined using a commercial immunoassay, expressed as nanomol per 
liter (nmol/l). The reference ranges were similar at each hospital laboratory. Sex hormone-
binding globulin (SHBG) was also measured for the majority of patients, but with different 
immunoassays with different reference ranges at each hospital laboratory. Thus, analyses of 
SHBG or the calculation of free testosterone based on total testosterone and SHBG101 were 
not included in the publications. 
 
The spirometries were carried out using Welch Allyn Pneumocheck 61000 at NRH, 
Vitalograph at Haukeland and Sensormedics VMAX227 at UNN. Spirometric variables 
included FVC and forced expiratory volume in 1 second (FEV1). The largest FVC and FEV1 
from at least three maneuvers were reported for patients at Haukeland and UNN, according to 
recommendations for spirometry maneuvers.102 At NRH, only one maneuver was performed 




Information regarding family status, educational level, smoking habits and physical activity 
were obtained from the questionnaire (Appendix II). The questionnaire also contained data on 
medication (antihypertensive, antidiabetic, asthmatic and/or lipid lowering medication), the 
prevalence of diabetes, pulmonary disease and dyspnea. Respondents with missing 
questionnaire data on antihypertensive treatment, lipid-lowering medication, asthma 
medication, diabetes or pulmonary disease were categorized as being without such treatment 
or disease, respectively. Study patients reporting that they had diabetes and/or received 
treatment with antidiabetic medication were classified as having diabetes, while those 
reporting having asthma and/or regularly used asthma medication were classified as having 
asthma. Dyspnea was assessed by one question where the participants were asked to state if 
they suffered “much”, “some” or “not at all” from dyspnea during the last 12 months. All 
patients reporting some or much were classified as having dyspnea. 
 
Data for family status and educational level were dichotomized according to living alone vs. 
married/cohabitant and college/university vs. lower education (paper I and II). Physical 
activity (paper II and III) was assessed by two questionnaire items, one assessing a low 
physical activity level (such as walking) and the other a high level (leading to sweating and 
breathlessness). Based on the responses, physical activity was divided into three categories 
(no, moderate and high activity) as described in a previous publication.103 Cigarette smoking 
was assessed by pack-years, calculated as number of cigarette packs smoked per day 
multiplied by the number of years smoked. Accordingly, the patients were categorized into 
four groups: never smokers, 0.1-9.9 pack-years, 10-19.9 pack-years and ≥ 20 pack-years 
(paper II and III).  
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4.2 The Tromsø Study (paper I and II) 
The control group was recruited from the Tromsø Study, a longitudinal population-based 
epidemiological study in Tromsø, Northern Norway. This study was initiated in 1974, 
primarily to identify possible risk factors for CVD. Large parts of the population have gone 
through repeated health examinations. Five surveys have been performed: Tromsø 1 (1974), 
Tromsø 2 (1979/1980), Tromsø 3 (1986/1987), Tromsø 4 (1994/1995), and Tromsø 5 (2001), 
which was conducted during the same time period as our follow-up survey. The sixth survey 
is being conducted now. Methods and attendance rates are previously published.104 Men 
treated with testosterone substitution were excluded before matching to our TCS study 
population. 
 
Tromsø covers a relatively large geographical area with both urban and rural population. The 
Tromsø study control group is representative for Norwegian males with regard to CV risk 
factors such as obesity and hypertension.104-107 Thus, this is a suitable control group even 
though the controls are recruited within a limited geographical region. 
 
In paper I, the control group consisted of 2847 males (born after 1925) who attended the 
Tromsø 5 survey, and had participated in at least one earlier survey. The median age was 63 
years (range 30-76 years). Systolic blood pressure (SBP), diastolic blood pressure (DBP) and 
BMI from Tromsø 5 were compared to the patients’ values at follow-up. SBP, DBP and BMI 
from either Tromsø 2, 3 or 4 were compared with the patients’ values at diagnosis.  In paper 
II, the control group consisted of men who participated in Tromsø 5. After excluding those 
who were older than 60 years, 1150 males with a median age of 48 years (range 30-60) 
constituted the control group. 
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4.3 Definitions of outcome variables  
Paper I: 
Paper I is both a longitudinal and a cross-sectional study. Blood pressure and BMI was 
evaluated both at diagnosis and at follow-up, and for BMI the 10-year change was calculated. 
SBP, DBP and BMI at time of diagnosis were characterized as pre SBP, pre DBP and pre 
BMI, respectively. The same variables at follow-up were characterized as post SBP, post DBP 
and post BMI. Hypertension and obesity was evaluated at follow-up only. Hypertension was 
defined as SBP ≥140 mmHg, and/or DBP ≥90 mmHg, and/or anti-hypertensive treatment,108 
according to the WHO guidelines. The applied 10-year BMI-change was calculated as the 
difference between post and pre BMI, divided by the observation time in years, multiplied by 
10 [(post BMI-pre BMI)*10/ observation time]. Obesity at follow-up was defined as BMI 
≥30,109 in agreement with the WHO guidelines. 
 
Paper II:  
Paper II is a cross-sectional study, reporting the prevalence of the metabolic syndrome at 
follow-up. Our study was planned and partially conducted before the WHO and NCEP 
definitions of the metabolic syndrome were published. Due to the lack of necessary data for 
applying these definitions of the metabolic syndrome, a modified NCEP definition was used. 
Hypertension and obesity was defined according to the WHO publications as indicated in 
paper I. Hypercholesterolemia was defined as total cholesterol ≥ 5.2 mmol/l63 and/or the use 
of lipid lowering drugs. Since blood glucose was measured non-fasting and only in a 
subgroup of patients, we instead applied patient-reported prevalence of diabetes and/or use of 
antidiabetic medication. According to our definition, metabolic syndrome was present if two 




(1) Hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg and/or medication) 
(2) Obesity (BMI ≥ 30 kg/m2) 
(3) Self-reported prevalence of diabetes 
(4) Hypercholesterolemia (serum total cholesterol ≥ 5.2 mmol/l and/or medication) 
Additionally, we performed analyses using a more restrictive definition of metabolic 
syndrome, defined as three or more components present.   
 
Paper III: 
Paper III is a cross-sectional study based on spirometries and questionnaire data from a subset 
of the study patients. The spirometry variables were expressed in absolute values (FVC and 
FEV1) and in percentages of predicted normal values (FVC%pred and FEV1%pred). 
Predicted normal values were calculated on the basis of sex, age and height, according to 
internationally approved equations.110 Restrictive lung disease was defined as FEV1/FVC ≥ 
70% and FVC%pred < 80%.111,112  
 
4.4 Statistical analyses 
The data were analyzed using SPSS versions 11.0 to 15.0 (SPSS Inc., Chicago, IL). All p-
values are two-tailed, with statistical significance set at p<0.05. The matching of cases and 
controls were performed at a group level, not an individual level, due to an inadequate 
number of young controls. Analyses with controls as reference group were included in paper I 
and II. The surgery group was used as reference when comparing the impact of different 
treatment modalities (paper I, II and III).  
 
Mean doses of cytotoxic drugs in the two chemotherapy groups were compared using 
Student’s t-test. Differences between treatment groups or between cases and controls with 
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respect to continuous variables were analyzed using multiple linear regression. All the 
continuous dependent variables analyzed in the papers were considered normally distributed. 
The regression coefficient, β, is used to indicate the mean difference in the dependent 
variable, when comparing different treatment groups.  
 
Dichotomous variables were analyzed using multiple logistic regression. Metabolic syndrome 
was also analyzed using ordinal logit regression, with the variable divided into quintiles (0, 1, 
2, 3, or all 4 components). The model calculated the probability for having a larger number of 
metabolic syndrome components. A test of parallel lines confirmed that the proportional odds 
assumption was met.  
 
All regression analyses were adjusted for age. Analyses of DBP and SBP were additionally 
adjusted for testosterone and BMI, and analyses of BMI were adjusted for testosterone. 
Analyses with metabolic syndrome as the outcome variable were additionally adjusted for 
total testosterone, smoking (pack years), physical activity, educational level and family status. 
Analyses of FVC%pred and FEV1%pred were additionally adjusted for total testosterone, 






Paper I  
Blood pressure and body mass index in long-term survivors of testicular cancer. 
This paper describes blood pressure, hypertension, BMI, obesity and change in BMI in a large 
group of unselected TCS with comparisons to controls from the general population. 
 
The study patients were categorized into four treatment groups: Surgery (n=242), RT (n=547), 
and two chemotherapy groups: cis≤850 mg (n=402) and cis>850 mg (n=98). A large part of 
the chemotherapy treated patients underwent retroperitoneal surgery (n=321, 64%) and 53 
(11%) received additional RT, primarily abdominal. The overall median follow-up was 11.2 
years (range 5-22). The RT group was significantly older than the surgery group at diagnosis 
(36 vs. 29 years, p<0.001) and at follow-up (48 vs. 41 years, p<0.001), whereas the cis>850 
group was significantly younger than the surgery group at follow-up (37 vs. 41 years, 
p=.005). 
 
At diagnosis, there were no differences between the treatment groups with respect to BMI, 
DBP or SBP in age-adjusted analyses. At follow-up, age-adjusted blood pressure values were 
significantly higher for the cis≤850 mg group (SBP: 4.1 mmHg, p=.005; DBP: 1.9 mmHg, 
p=.04) and the cis>850 group (SBP: 5.0 mmHg, p=.02; DBP: 3.4 mmHg, p=.01) compared 
with the surgery group. These differences were basically unchanged after adjusting for BMI 
and testosterone. BMI did not differ significantly between the treatment groups.  
 
The percentage of persons with hypertension at follow-up was 39% in the surgery group, 54% 
in the RT group, 50% in the cis≤850 group and 53% in the cis>850 group. Chemotherapy-
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treated patients had increased odds for hypertension at follow-up compared to the surgery 
group, highest for the cis>850 group (odds ratio [OR] =2.4, 95% confidence interval [CI] 1.4-
4.0). The cis>850 group had a significantly higher 10-year BMI-increase, and a higher 
prevalence of obesity at follow-up than the surgery group.  
 
Compared with healthy controls, chemotherapy-treated patients had, at follow-up, increased 
SBP, DBP, excessive BMI-increase and a higher prevalence of hypertension. SBP, DBP and 
10-year BMI-increase in surgery/RT treated patients did not differ from healthy controls. 
Though, patients treated with RT had increased hypertension rates. 
 
In conclusion, hypertension and augmented weight gain were identified as potential long-term 
side-effects after treatment with cisplatin-based chemotherapy, in particular after cumulative 
cisplatin doses above 850 mg.  
 
Paper II  
Components of the metabolic syndrome in long-term survivors of testicular cancer. 
This paper describes the prevalence of the metabolic syndrome according to a modified 
NCEP definition in a large group of unselected TCS with comparisons to controls from the 
general population. 
 
The study participants were categorized into the following four groups: Surgery (n=225), RT 
(n=446), cis≤850 (n=376) and cis>850 (n=88). Median follow-up was 11.1 years (range 5-
22). Compared with the surgery group, the RT group was older at diagnosis and at follow-up 
(p<0.001, both), while the Cis>850 group was younger at diagnosis (p=.016) and at follow-up 
(p<0.001), and had a shorter observation time (p=.001). 
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The metabolic syndrome was observed in 33% of patients in the surgery group, 42% in the 
RT group, 40% in the cis≤850 group and 48% in the cis>850 group. Both chemotherapy 
groups had increased odds for metabolic syndrome compared with the surgery group, highest 
for the Cis>850 group (OR 2.8, 95% CI 1.6-4.7). Also, the Cis>850 group had increased odds 
for metabolic syndrome compared with the control group (OR 2.1, 95% CI 1.3-3.4). The 
association between metabolic syndrome and the Cis>850 group was strengthened after 
adjusting for testosterone, smoking, physical activity, education and family status.  
 
On the basis of our more restrictive definition of the metabolic syndrome (≥3 components 
included), the syndrome was observed in overall 8% of the study patients. Compared with the 
surgery group, only the Cis>850 group had increased odds for metabolic syndrome, with an 
OR of 2.6 (95% CI 1.1-6.0).  When using ordinal logit regression, both chemotherapy groups 
had increased probability for having a larger number of metabolic syndrome components 
compared with the surgery group, with highest odds for the cis>850 group (OR=3.1, 95% CI 
2.0-5.0). Compared with controls, the surgery and RT groups had lower odds, while the 
cis>850 group had higher odds for having a larger number of metabolic syndrome 
components (OR 2.1, 95% CI 1.4-3.3). 
 
Metabolic syndrome was positively associated with cumulative cisplatin (p=.001), bleomycin 
(p=.001) and etoposide doses (p=.002) in age-adjusted analyses. Cumulative vinblastine dose 
was not associated with metabolic syndrome (p=.27). Logistic regression using a backward 
stepwise model with all four chemotherapy agents and age included, left only age and 
cumulative cisplatin dose as significant variables. 
 
In conclusion, TCS treated with high cumulative cisplatin doses had an increased risk of 
developing the metabolic syndrome in comparison to surgery treated patients or to controls.  
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Paper III  
Pulmonary function in long-term testicular cancer survivors. 
This paper describes the pulmonary function assessed by spirometries and a questionnaire in a 
large group of unselected TCS. 
 
The participants were categorized into the following five groups: Surgery (n=202), RT 
(n=449), cis≤850 (n=306), cis>850 (n=62) and cis/pulmsurg (n=30). Only two patients in the 
RT group and three chemotherapy-treated patients received mediastinal irradiation. Only two 
patients received more than 360 mg bleomycin. Median observation time was 11.2 years 
(range 5-21). The RT group was significantly older than the surgery group at diagnosis 
(p<.001) and follow-up (p<.001), while the cis>850 group was younger than the surgery 
group at follow-up (p=.002). 
 
Compared with the surgery group, the cis>850 and cis/pulmsurg groups had considerably 
lower age-adjusted FVC (cis>850: β=-0.37, p=.001; cis/pulmsurg: β=-0.58, p<.001), FEV1 
(cis>850 β=-0.24, p=.014; cis/pulmsurg β=-0.55, p<.001), FVC%pred (cis>850 β=-8.3; 
cis/pulmsurg β=-10.5, both p<.001) and FEV1%pred (cis>850 β=-6.8, p=.003; cis/pulmsurg 
β=-12.4, p<.001). Adjustment for total testosterone, BMI, smoking and physical activity did 
not change these associations.  
 
In a multiple model including age and the chemotherapy variables (bleomycin, cisplatin, 
etoposide and vinblastine), the cumulative bleomycin dose (p=.034), cisplatin dose (p<.001) 
and age (p<.001) were significantly associated with FVC%pred. Only cisplatin and age 
(p<.001, both) were significantly associated with FEV1%pred. FVC%pred tended to be lower 
for men with initially stage IV disease in comparison to men with stage I-III (88.6% vs. 
94.2%, p=.07). FEV1%pred did not differ between these two groups (89.9% vs. 91.9%, 
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p=.44), and the risk for restrictive lung disease was comparable (18.2% vs. 17.5%, OR=1.01, 
95% CI 0.94-1.07). 
 
Overall, 101 (10%) patients reported having dyspnea and 27 (2.6%) were classified as having 
asthma. The cis>850 group had the highest percentage of both dyspnea and prevalent asthma, 
but their odds did not differ significantly from the surgery group. Eight percent of all patients 
had restrictive lung disease, with the highest prevalence in the cis>850 (17.7%) and 
cis/pulmsurg group (16.7%). Compared with the surgery group, the cis>850 and cis/pulmsurg 
groups had ORs for restrictive disease at 3.1 (95% CI 1.3-7.3) and 2.5 (95% CI 0.8-7.6), 
respectively.  
 




6.1 Methodological considerations 
6.1.1 General aspects 
The findings in this thesis are based on data from a follow-up study where information on 
treatment (exposure) and the outcome variables were collected simultaneously, although the 
treatment had been administered at an earlier point in time. Cross-sectional studies are well 
suited for detecting differences between samples. However, they are based on prevalence and 
not incidence of the outcome variable. Thus, cross-sectional studies do not necessarily yield 
information on causal relationships, but can indicate whether there are associations between 
exposure and outcome.113  
 
It has been speculated whether TC itself is associated with an increased CVD risk, 
irrespective of administered treatment.86,88 Thus, it is important to compare results on CV risk 
factors and the metabolic syndrome with controls representing the general population. Due to 
the relatively young age of our study patients and the limited follow-up, we do not have 
sufficient data on CV events.114 CV risk factors and the metabolic syndrome are therefore 
surrogate endpoints for CVD.  
 
In epidemiological and clinical studies, the conclusion is based on an estimated association 
between the exposure and the outcome variable. The estimate should be a valid measure for 
the association. It is important to ensure both the internal validity (the degree to which the 
observed associations are representative for the study population) and the external validity 
(the degree to which the results also are applicable for other study populations).113 The 
internal validity depends on to what degree systematic errors (bias) occur. Systematic errors 
can be divided into selection bias, information bias and confounding, which may all cause 
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incorrect estimates.115 The internal validity is a prerequisite for the external validity, and will 
thus be discussed in more detail in the following pages. 
 
6.1.2 Selection bias 
The recruitment of study subjects and factors influencing study participation may lead to 
selection bias. This type of systematic error occurs when the association between exposure 
and outcome differs from those who participate (responders) and those who do not participate 
in the study (non-responders).115  
 
Our study recruited unselected survivors of unilateral germ cell TC. All Norwegian men who 
were eligible (chapter 4) were invited to participate, and overall 81% participated in this 
study. This high participation rate makes it unlikely that our findings are influenced by 
selection bias. Additionally, based on the information we have on non-responders, they did 
not differ from the responders with regard to age at follow-up, stage, histology or treatment as 
described in section 4.1.1.  
 
6.1.3 Information bias 
Information bias can occur when measurement or classification of information obtained from 
or about the study participants is incorrect. Information is being misclassified if the actual 
variable is measured on a categorical scale and the misclassification leads to an individual 
being classified into an erroneous category.115  
 
Misclassification of lifestyle indicators, such as smoking and physical activity, may place the 
subjects in more “healthy” categories than what is the true instance.113 Self-reporting of 
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medical conditions and treatment may lead to both under-reporting and over-reporting, while 
reporting of familiar conditions such as asthma and diabetes is often accurate.116 Nevertheless, 
it is unlikely that possible misclassifications of the questionnaire variables depend on the 
administered treatment.  
 
Blood pressure is characterized by large spontaneous variations and several measurements are 
required to diagnose hypertension according to the guidelines.108 Our blood pressure 
measurements were not in agreement with these guidelines. However, our observed 
differences between the treatment groups with regard to SBP, DBP and hypertension was 
probably unaffected by this lack of adherence to the guidelines since all study participants had 
their blood pressure measured only once. Controls from the Tromsø study had their blood 
pressure measured three times at each survey, and we chose to use their first measurement to 
achieve as similar conditions for study patients and controls as possible.  
  
The reproducibility of height and weight measurements is excellent and these are among the 
most precise biological measurements.117 The calculation of BMI in this thesis is based on 
measurements of weight and height, not self-reported values. Thus, it is unlikely that the 
estimation of BMI was biased.  
 
Blood samples should be collected at the same time of the day for all participants due to the 
diurnal variation of testosterone. Most of our study patients had their blood samples drawn 
before 1200 in the morning, when the testosterone levels are highest.118 While there may exist 
variability between different laboratories with respect to measurements of sex steroids in 
general, total testosterone variability is within acceptable limits.119  
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Spirometry variables often show large intra individual variability, and it is recommended that 
each person performs at least three spirometry maneuvers.102 The spirometry values for 
patients at NRH, having performed only one spirometry each, could possibly be biased. 
However, no interaction113 was observed between institution and treatment group (categorical 
variables) for any of the outcome variables described in paper III.  
 
6.1.4 Confounding 
A simple definition of confounding would be the confusion, or mixing, of effects.115 Thus, 
confounding occurs when the estimated association between the outcome variable and the 
exposure variable is distorted by one or several other variables. Confounding can be 
controlled by either adjustments in multivariate analyses or stratification. 
 
The prevalence of CV morbidity, CV risk factors, and the metabolic syndrome increase 
substantially with increasing age,99 while the pulmonary function decreases with increasing 
age.110,120 Since there are significant differences in age at follow-up between our treatment 
groups and between patients and controls, age is a possible confounder of our results. Thus, it 
was essential to adjust for age in all the analyses of outcome variables.  
 
 Another possible confounder is serum testosterone. Our estimated associations between the 
cis>850 group and the outcome variables could be due to low serum testosterone values, and 
not the chemotherapy treatment itself. Consequently, additional adjustments for serum 
testosterone were performed to potentially clarify the effect of testosterone. This was also the 
case for other life-style factors. 
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6.2 Discussion of results  
6.2.1 Cardiovascular risk factors and the metabolic syndrome 
In paper I and II, we found that previous cisplatin-based treatment to TCS was associated with 
increased age-adjusted SBP and DBP and a higher prevalence of hypertension, obesity and 
the metabolic syndrome in comparison to TCS treated with surgery only. The risk factor 
levels were highest after cumulative cisplatin doses above 850 mg. This heavily treated group 
also had increased CVD risk compared with the control group.  
 
Our blood pressure data are in accordance with Meinardi and co-workers,86 who reported 
higher SBP and DBP in cisplatin-treated patients compared with orchiectomized patients 
observed in a surveillance program. Our results do not, however, support the findings by 
Huddart and co-workers who did not observe any differences in blood pressure levels 
between the treatment groups.87 Several investigators have reported hypertension as a possible 
long-term complication in TCS after cisplatin-based chemotherapy,14-16,18,76,85,86 with reported 
hypertension rates between 13% and 39%. Our hypertension rates in chemotherapy treated 
patients were higher, probably due to the inclusion of patients receiving antihypertensive 
medication and the application of a more liberal hypertension definition.108  
 
BMI measured as a continuous variable did not differ between the treatment groups, 
corroborating other studies.86,87,121,122 We found that the cis>850 group had a higher 
prevalence of obesity at follow-up compared with the surgery group, and also an excessive 
weight gain compared with both the surgery group and healthy controls, supporting previous 




Hypertension, obesity and hypercholesterolemia all seem to be involved in the increased risk 
for metabolic syndrome in our heavily cisplatin-treated patients. Our hypercholesterolemia 
rates of 67% and 73% after standard and high cumulative cisplatin doses, respectively, are in 
line with other studies reporting rates at 67% to 84%.18,77,85,86   
 
As we observed that only chemotherapy treated patients had an increased risk for the 
metabolic syndrome, our data are inconsistent with the Dutch study by Nuver et al.88 They 
found a higher prevalence of the metabolic syndrome in Stage I patients treated with surgery 
alone than in chemotherapy treated patients, although both groups had a significantly 
increased prevalence of the metabolic syndrome in comparison to controls. A subset of our 
study patients was recently described with regard to inflammatory markers and the metabolic 
syndrome, after further laboratory analyses in blood samples.123 Wethal and co-workers found 
that chemotherapy treated patients, irrespective of cisplatin dose, had the highest risk for 
metabolic syndrome in comparison to surgery only patients (OR 3.7). In addition, they 
noticed that also RT treated patients had a significantly increased risk for the metabolic 
syndrome (OR 3.3). The most probable explanation for the discrepancy between our and the 
Nuver and Wethal results is the different criteria applied in the definition of the metabolic 
syndrome.  
 
While mediastinal irradiation has been associated with increased risk for CVD,6,72,73 there are 
conflicting data regarding the association between infradiaphragmatic RT and CVD 
risk.6,87,124 SBP, DBP, BMI, hypertension, obesity and metabolic syndrome rates for RT 
treated patients were not significantly different from the surgery group in our study, which is 
in line with the only other publication reporting CV risk factors after infradiaphragmatic RT.87 
On the other hand, this British study did find an increased risk for CV events following RT 
alone or in combination with chemotherapy. It is, however, possible that the increased risk for 
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CVD after RT in the British study is mediated via other mechanisms such as elevation of 
inflammation markers.123 Assuming that an increased CVD risk in TCS is mediated via the 
classical CV risk factors, our results are in line with a relatively recent Dutch study indicating 
that patients treated with infradiaphragmatic RT alone did not have any increased CVD 
risk.124 In this study, cisplatin-based treatment was associated with a 1.5 to 1.9-fold increased 
risk for CVD in comparison to surgery. 
 
Paper I had both a longitudinal and a cross-sectional design. Although blood pressure 
measurements prior to treatment probably were biased leading to temporarily increased 
values, an important finding is that blood pressure measurements did not differ between 
treatment groups at diagnosis. Thus, our observed differences in blood pressure develop later 
probably as a result of cisplatin-based treatment. This is the first study comparing blood 
pressure measurements between TCS and controls from the general population, in which the 
surgery/RT treated patients did not differ from the controls. Hence, it is unlikely that an 
increased risk for CVD is related to the TC diagnosis itself.  
  
Cisplatin-based chemotherapy may lead to Leydig cell insufficiency.79 Low endogenous 
testosterone levels are associated with increased levels of cardiovascular risk factors,125-127 the 
metabolic syndrome128,129 and an increased risk of CVD mortality.130,131 However, cisplatin-
based treatment was associated with increased levels of CV risk factors and the metabolic 
syndrome even after adjusting for serum total testosterone, indicating other causative 
mechanisms.  
 
Hypomagnesemia, a potential consequence of cisplatin-induced nephrotoxicity,132 is 
associated with the metabolic syndrome133,134 and may be a possible link between cisplatin-
based chemotherapy and the components of the metabolic syndrome. Mean serum Mg levels 
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in our study did not differ between the Cis>850 and the surgery group, and serum Mg was not 
associated with the metabolic syndrome. However, it is particularly the intracellular levels of 
Mg which are reduced following cisplatin administration,135 and the intracellular levels are 
also probably more important in the metabolic and vascular regulation.133 
 
Another possible explanation for our findings in paper I and II is a chemotherapy-dependent 
induction of endothelial dysfunction.122,136 The endothelium is involved in the regulation of 
vascular tone, metabolism of lipoproteins and in immune response.137 There is evidence for a 
cisplatin-induced endothelial activation from in vitro studies,138,139 and it has been shown that 
the level of von Willebrand factor, a marker of endothelial activation, increases during 
cisplatin-based chemotherapy.140  
 
6.2.2 Pulmonary function  
In paper III, we found that patients treated with large cumulative cisplatin doses, or with 
chemotherapy combined with pulmonary surgery, had a significantly reduced pulmonary 
function compared with patients treated with surgery alone. The heavily chemotherapy-treated 
patients also had a higher risk for restrictive lung disease.  
 
Prior studies evaluating pulmonary function after treatment for TC have focused on BPT and 
thus included chemotherapy treated patients only. In the majority of these studies, the 
conclusion is that possible reductions in the pulmonary function during or shortly after 
treatment are normalized at follow-up.90,93,95-97 Hence, this is the first study indicating that 
large cumulative chemotherapy doses are associated with reduced pulmonary function several 
years after treatment. Previous studies did not detect any associations between cumulative 
bleomycin dose and spirometry values,90,95,98 except in one study which showed an 
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association between bleomycin dose and VC.96 Although we found bleomycin to be 
significantly associated with FVC%pred, our results indicate a stronger association between 
the cumulative cisplatin dose and both FVC%pred and FEV1%pred. These results are 
supported by Stuart et al as they found VC to correlate with number of chemotherapy courses, 
but not with the cumulative bleomycin dose.141 Since the maximum cumulative bleomycin 
doses have been set at 300-360 mg, the cumulative cisplatin rather than bleomycin dose 
emerge as the pivotal factor influencing long-term pulmonary function negatively in TC 
survivors.  
 
Low serum testosterone levels have been associated with decreased spirometric variables142 
and an increased risk for respiratory disease mortality in epidemiological studies.131,143 Thus, 
part of our findings could be explained by low serum testosterone levels. After controlling for 
testosterone as a potential confounder, the cumulative cisplatin dose still had a highly 
significant influence on the pulmonary function. Cisplatin-based chemotherapy has several 
long-term organ toxicities,78 and it is not unlikely that this treatment also affects the lungs.  
  
The reduced pulmonary function among men in the cis>850 group may be caused by other 
factors than the cytotoxic treatment alone. High tumor burden in the lungs and/or recurrent 
disease may affect the pulmonary status. Our results indicate that men in the cis>850 
subgroup with stage IV disease tended to have a lower FVC%pred, but FEV1%pred and the 
risk for restrictive lung disease did not differ from those with stage I-III disease.  
 
Although the majority of our study patients had subclinically reduced pulmonary function, it 
may possibly further develop into clinical pulmonary disease. In fact, the effect on the 
pulmonary function by large cumulative cisplatin doses equals 2-4-fold the effect of smoking. 
In a large international study, TCS previously treated with chemotherapy were reported to 
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have increased respiratory disease mortality with a SMR at 2.53.23 Further, population-based 
epidemiological studies have shown an association between pulmonary function and all-cause 





7. CONCLUSIONS AND IMPLICATIONS FOR FUTURE RESEARCH 
In this thesis we have identified hypertension, obesity and an increased risk for the metabolic 
syndrome as possible long-term side-effects after high doses of cisplatin-based chemotherapy 
in an unselected group of TCS. Treatment with infradiaphragmatic RT was not associated 
with any increased CV risk factor levels. In paper III we identified reduced pulmonary 
function as a long-term side-effect following treatment with high cumulative cisplatin doses 
or with chemotherapy combined with pulmonary surgery. Our findings regarding the 
pulmonary function in TCS are novel and due to the cross-sectional study design, our results 
are only hypothesis-generating.  
 
In summary, our results indicate that treatment with large doses of cisplatin-based 
chemotherapy affects both CV risk factors and the pulmonary function in a manner which 
displays similarities with premature aging. Our findings need to be confirmed by large 
prospective studies. Future studies should include patients with a longer follow-up to obtain 
sufficient data on CV events, and if possible, the evaluation of CV risk profile and pulmonary 
function before treatment is administered. Basic research in this field is also required to 
clarify the mechanisms behind various chemotherapy-related toxicity effects.   
 
Our data suggest that TCS treated with cisplatin-based chemotherapy should be followed 
regularly beyond the standard 10-year follow-up period, with regard to both CV risk factors 
and the pulmonary function. There is a great need for national follow-up guidelines for these 
cancer survivors. All physicians involved in the treatment and follow-up of these men should 
be aware of the possible side-effects related to treatment and offer information about potential 
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Forespørsel om å delta i etterundersøkelse av pasienter behandlet 
for testikkelkreft 
 
Takket være medisinske framskritt helbreder vi stadig flere kreftpasienter. Dette gjelder 
spesielt pasienter med testikkelkreft. Etter 1980 har behandlingen av testikkelkreft gjort store 
framskritt, noe som også norske pasienter har hatt nytte av. Vi vet at det i Norge i dag lever 
ca. 6.000 menn som har fått behandling for testikkelkreft. 
 
De fleste kreftsentra i verden kontrollerer sine testikkelkreftpasienter årlig i 10 år eller hele 
livet ut, først og fremst for å kartlegge og behandle eventuelle senbivirkninger etter at nye 
behandlingsmetoder ble innført på slutten av 70-tallet. 
 
Av kapasitetsmessige grunner er vi ved Kreftavdelingen nødt til å avslutte rutinekontrollene 
etter 5 – 10 år. Vi vet at ca. 95% av pasienter behandlet for testikkelkreft kureres. Siden de 
fleste behandles i ung alder er det viktig at behandlingen ikke medfører uakseptable 
seneffekter. Av denne grunn er det nødvendig at man fra tid til annen utfører etterkontroller 
mht evt legemlige og psykiske senbivirkninger hos våre pasienter.  
 
Som ledd i en nasjonal etterundersøkelse av pasienter som har vært behandlet for 
testikkelkreft planlegger vi ved Kreftavdelingen, Regionsykehuset i Tromsø en større 
oppfølging av alle nordnorske pasienter som er helbredet for testikkelkreft i tiden 1980–1994. 
 
Du forespørres herved om å delta i undersøkelsens to deler: 
 
1. Spørreskjemaundersøkelsen. 
Hvis du samtykker i det, vil du få tilsendt et spørreskjema med 219 
 spørsmål som vurderer din legemlige og psykiske helsetilstand og din sosiale situasjon 
(arbeid, familie). Det vil ta ca. 1 time å fylle ut dette skjema. 
 
2.  Poliklinisk undersøkelse. 
Dette er en poliklinisk undersøkelse ved Kreftavdelingen, Regionsykehuset i Tromsø hvor 
vi vil foreta en klinisk undersøkelse, blodprøver, lungetest, hørselsundersøkelse, og for 
dem som samtykker i det, en sædanalyse.  
På sykehuset vil du også bli bedt om å fylle ut et spørreskjema på knapt 200 spørsmål (ca. 
en ½ time å fylle ut). Det vil bli avsatt tid for dette og du vil få hjelp ved behov. 
Noen vil også få en samtale om forholdet til din egen sykdom. Denne samtalen vil ta 
utgangspunkt i det første spørreskjemaet. 
 
For de pasientene som allerede har avsluttet sine faste kontroller ved Regionsykehuset i 
Tromsø vil vi ordne med henvisning fra privatlege/sykehuslege, slik at reiseutgifter 
refunderes av trygdekontoret som ved en vanlig poliklinisk kontroll ved RiTø (som regel 
bruk av offentlige transportmidler). 
 
Din deltakelse i denne spørreundersøkelsen er frivillig. Du kan når som helst trekke deg fra 
undersøkelsen uten at dette får konsekvenser for din videre oppfølging. De innsamlede 
opplysninger kan i så tilfelle kreves slettet.  
 
Alle undersøkelsesdata vil bli behandlet konfidensielt, og ved behandling av resultatene vil 
data bli anonymiserte. Det vil si at dataene ved offentliggjøring ikke kan knyttes til personer. 
Alle data vil bli samlet i en database ved Radiumhospitalet i Oslo.  
 
Om du er villig til å delta i denne etterundersøkelsen vil vi be om at du signerer dette 
informasjonsskrivet (kopien skal du beholde). For å kunne planlegge de videre undersøkelser, 
vil vi be deg svare på spørsmålene på vedlagte grønne skjema. Både underskrevet 
informasjonsskriv (dette) og utfylt grønt skjema returneres snarest i vedlagte frankerte 
konvolutt. 
 
Kontaktperson for studien ved Regionsykehuset i Tromsø er  
overlege dr. med. Roy M. Bremnes  
Kreftavdelingen  
Regionsykehuset i Tromsø  
9038 Tromsø  





Jeg bekrefter at jeg er blitt informert om undersøkelsen, samt fått en kopi av dette 
informasjonsskrivet. Jeg samtykker i å delta i studien. Jeg er opplyst om at min deltakelse i 




_____________________________     ______________ 










For at avdelingen lettere skal kunne planlegge den polikliniske undersøkelsen, ber vi deg 
svare på følgende spørsmål: 
 
1. Er du villig til å delta i spørreskjemaundersøkelsen om 






2. Er du villig til å komme til en poliklinisk kontroll ved 
Kreftavdelingen, Regionsykehuset i Tromsø med 











3. Kan du tenke deg å avlevere en sædprøve under den 
polikliniske undersøkelsen, enten fordi du selv er  
interessert i resultatet eller fordi du kunne tenke deg å 











4. Går du fremdeles til rutinekontroll ved RiTø? 
 
Nei ………… Ja ………….. 
 











Navn:    
  Sign. 
 
Fødselsdato: 






Tlf. arbeid:  Tlf privat:   
 
 
Legen som eventuelt skal få opplysninger om deg som følge av undersøkelsen  
(din faste lege): 
 
Navn: ………………………………………………………………………… 
 
 
Adresse: ……………………………………………………………………… 
 
 












 
 
 
